PORTFOLIO NEWS Gritstone Oncology Announces Proposed Public Offering of Common Stock April 22, 2019 Read More » Surrozen Appoints Dr. Trudy Vanhove as Chief Medical Officer April 11, 2019 Read More » NGM Bio Announces Pricing of Initial Public Offering April 3, 2019 Read More » Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001 March 21, 2019 Read More » NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer March 20, 2019 Read More » Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidate March 14, 2019 Read More » Immune Design acquired by Merck for approx. $300M February 21, 2019 Read More » Kallyope Inc. Appoints Brett Lauring as Chief Medical Officer February 5, 2019 Read More » Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer January 4, 2019 Read More » Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs January 3, 2019 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Next »
Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001 March 21, 2019 Read More »
NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer March 20, 2019 Read More »
Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidate March 14, 2019 Read More »
Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer January 4, 2019 Read More »
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs January 3, 2019 Read More »
